Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethistron is a pharmaceutical product developed and marketed by Rowez Life Sciences, containing the active ingredient norethisterone (also known as norethindrone). Norethisterone is a potent, synthetic progestin belonging to the 19-nortestosterone family. It functions primarily as an agonist at the progesterone receptor, mimicking the physiological effects of endogenous progesterone. By activating these receptors in the hypothalamus and pituitary gland, it inhibits the secretion of gonadotropins, thereby preventing ovulation. In the uterus, it transforms a proliferative endometrium into a secretory one and, at higher doses, can treat endometriosis by inducing decidualization and subsequent atrophy of endometrial tissue. Ethistron is typically indicated for the management of various gynecological conditions, including abnormal uterine bleeding, primary and secondary amenorrhea, and endometriosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norethisterone.